RxDoctor Payments Data

Zepure Kouyoumdjian, DO

Neurology · Morgan Hill, CANPI 1235326232

Payments from drug & device makers

$253,063in general payments, 2019–2025

Across 1,587 payments — averaging $159.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$119K
  • Teva Pharmaceuticals USA, Inc.$82K
  • Amgen$20K
  • Biohaven Pharmaceutical Holding Company Ltd.$5K
  • Amneal Pharmaceuticals LLC$4K
  • Avanir Pharmaceuticals, Inc.$2K
  • plus $20K from 54 others

What the payments were for

  • Consulting fees$1,1500%
  • Speaking & faculty fees$201,18179%
  • Travel & lodging$17,1237%
  • Food & beverage$33,27613%
  • Education$3330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)251$118,667
Teva Pharmaceuticals USA, Inc.200$82,244
Amgen(2 entities)74$20,363
Biohaven Pharmaceutical Holding Company Ltd.32$5,386
Amneal Pharmaceuticals LLC11$3,630
Avanir Pharmaceuticals, Inc.69$1,920
SK Life Science, Inc.79$1,726
UCB, Inc.64$1,575
AstraZeneca(2 entities)71$1,378
Neurocrine Biosciences, Inc.44$1,148
Boston Scientific15$994
Biogen34$915
Lilly USA, LLC45$783
Jazz Pharmaceuticals Inc.33$745
Impel Pharmaceuticals Inc.49$707
MDD US Operations, LLC36$654
Bristol Myers Squibb39$602
Greenwich Biosciences, Inc.24$596
Pfizer26$567
Lundbeck LLC28$535
Acadia Pharmaceuticals Inc29$479
Argenx US, Inc.15$436
Biohaven Pharmaceuticals, Inc.36$378
Acorda Therapeutics, Inc17$370
Noctrix Health, Inc.1$349
Sumitomo Pharma America, Inc.15$325
Neurelis, Inc.10$302
Mallinckrodt Enterprises LLC14$295
Otsuka America Pharmaceutical, Inc.15$290
Johnson & Johnson(2 entities)10$284
Eisai Inc.11$281
Sunovion Pharmaceuticals Inc.14$277
Adamas Pharmaceuticals, Inc.15$269
Mallinckrodt Hospital Products Inc.11$249
Kyowa Kirin, Inc.11$242
Genentech USA, Inc.7$162
Bausch Health US, LLC11$161
EMD Serono, Inc.6$160
Merz Pharmaceuticals, LLC6$151
GE HealthCare5$147
Ironshore Pharmaceuticals Inc.6$135
Banner Life Sciences, LLC6$129
GRT US Holding, Inc.4$122
Octapharma USA, Inc.4$122
ANI Pharmaceuticals, Inc.5$120
Arbor Pharmaceuticals, Inc.6$117
CSL Behring5$112
Novartis5$103
Corium, LLC4$99
Supernus Pharmaceuticals, Inc.6$94
Zyla Life Sciences, Inc.4$88
Grifols USA, LLC3$74
Vanda Pharmaceuticals Inc.2$69
TG Therapeutics, Inc.2$62
Takeda Pharmaceuticals U.S.A., Inc.4$62
Upsher-smith Laboratories LLC3$57
Life Molecular Imaging Ltd2$55
Averitas Pharma Inc.2$51
Axsome Therapeutics, Inc.2$50
Ipsen Biopharmaceuticals, Inc2$50

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$253,063 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$978,955
Medicare patients
784
Services billed
59,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuedextaDextromethorphan Hbr/Quinidine52$84,627
Aimovig AutoinjectorErenumab-Aooe60$62,469
Nurtec OdtRimegepant Sulfate26$39,125
Ajovy AutoinjectorFremanezumab-Vfrm41$37,630
UbrelvyUbrogepant33$36,704
Ajovy SyringeFremanezumab-Vfrm33$23,521
Emgality PenGalcanezumab-Gnlm29$20,138
NeuproRotigotine17$19,346
Emgality SyringeGalcanezumab-Gnlm25$16,447
Rivastigmine33$9,035
RivastigmineRivastigmine Tartrate79$8,773
Rasagiline Mesylate12$8,120
Memantine Hcl105$3,575
Gabapentin135$2,745
Pregabalin110$2,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$1,920$84,62752 claims
PfizerNurtec Odt$567$39,12526 claims
AbbVieUbrelvy$118,667$36,70433 claims
UCB, Inc.Neupro$1,575$19,34617 claims
Upsher-smith Laboratories LLCTopiramate$57$1,54096 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in Morgan Hill

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →